216 related articles for article (PubMed ID: 22350800)
1. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.
Journo-Gershfeld G; Kapp D; Shamay Y; Kopeček J; David A
Pharm Res; 2012 Apr; 29(4):1121-33. PubMed ID: 22350800
[TBL] [Abstract][Full Text] [Related]
2. CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors.
Zaiden M; Rütter M; Shpirt L; Ventura Y; Feinshtein V; David A
Mol Pharm; 2018 Sep; 15(9):3690-3699. PubMed ID: 29957956
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
[TBL] [Abstract][Full Text] [Related]
4. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid.
Yin S; Huai J; Chen X; Yang Y; Zhang X; Gan Y; Wang G; Gu X; Li J
Acta Biomater; 2015 Oct; 26():274-85. PubMed ID: 26300335
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery.
Liu Y; Sun J; Cao W; Yang J; Lian H; Li X; Sun Y; Wang Y; Wang S; He Z
Int J Pharm; 2011 Dec; 421(1):160-9. PubMed ID: 21945183
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
10. CD44 Receptor Targeting and Endosomal pH-Sensitive Dual Functional Hyaluronic Acid Micelles for Intracellular Paclitaxel Delivery.
Liu Y; Zhou C; Wang W; Yang J; Wang H; Hong W; Huang Y
Mol Pharm; 2016 Dec; 13(12):4209-4221. PubMed ID: 27796093
[TBL] [Abstract][Full Text] [Related]
11. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
13. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.
Yang XY; Li YX; Li M; Zhang L; Feng LX; Zhang N
Cancer Lett; 2013 Jul; 334(2):338-45. PubMed ID: 22776563
[TBL] [Abstract][Full Text] [Related]
15. Integrin-targeted nano-sized polymeric systems for paclitaxel conjugation: a comparative study.
Eldar-Boock A; Blau R; Ryppa C; Baabur-Cohen H; Many A; Vicent MJ; Kratz F; Sanchis J; Satchi-Fainaro R
J Drug Target; 2017; 25(9-10):829-844. PubMed ID: 28737432
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Larson N; Yang J; Ray A; Cheney DL; Ghandehari H; Kopeček J
Int J Pharm; 2013 Sep; 454(1):435-43. PubMed ID: 23827653
[TBL] [Abstract][Full Text] [Related]
17. High paclitaxel-loaded and tumor cell-targeting hyaluronan-coated nanoemulsions.
Kim JE; Park YJ
Colloids Surf B Biointerfaces; 2017 Feb; 150():362-372. PubMed ID: 27823852
[TBL] [Abstract][Full Text] [Related]
18. Investigation on vitamin e succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy.
Hou L; Tian C; Chen D; Yuan Y; Yan Y; Huang Q; Zhang H; Zhang Z
Eur J Pharm Sci; 2019 Dec; 140():105071. PubMed ID: 31525433
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.
Zhang R; Luo K; Yang J; Sima M; Sun Y; Janát-Amsbury MM; Kopeček J
J Control Release; 2013 Feb; 166(1):66-74. PubMed ID: 23262201
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Miller K; Eldar-Boock A; Polyak D; Segal E; Benayoun L; Shaked Y; Satchi-Fainaro R
Mol Pharm; 2011 Aug; 8(4):1052-62. PubMed ID: 21545170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
